For patients undergoing percutaneous coronary intervention (PCI), tailoring antiplatelet therapy based on the results of platelet function testing makes no difference in the risk of recurrent ischemic ...

In patients undergoing percutaneous coronary intervention (PCI), intensifying antiplatelet therapy based on platelet reactivity testing reduces cardiovascular mortality and stent thrombosis, according ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...

March 6, 2009 (Munich, Germany) — More evidence that patients with a low platelet responsiveness to clopidogrel have an increased risk of stent thrombosis has come from a new study, with the ...

Haemonetics Corporation HAE recently initiated commercial roll out of its four-channel TEG 6s PlateletMapping ADP & AA assay cartridge globally. Designed to be used with the TEG 6s Hemostasis Analyzer ...

Please provide your email address to receive an email when new articles are posted on . In comatose survivors of out-of-hospital cardiac arrest who undergo treatment with PCI and hypothermia, ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

The coronavirus disease-19 (COVID-19) pandemic that emerged in Wuhan, China, in late December 2019 spread rapidly throughout the world and has caused over 6.5 million deaths. The disease is caused by ...